Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

University of Cologne28 enrolled

Overview

The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Relapsed NLPHL

Interventions

OfatumumabDRUG

300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * relapsed nodular lymphocyte predominant hodgkin lymphoma * age 18 - 75 * review of diagnosis by experienced pathologist * no major organ dysfunction Exclusion Criteria: * classical hodgkin lymphoma * CD20 antibody treatment within the last 6 months prior enrollment * chronic or current infectious disease requirering systemic antibiotics * other past or current malignancy

Locations (1)

1st Department of Medicine, Cologne University Hospital

Cologne, Germany

Outcomes

Primary Outcomes

Overall response rate

Time frame: 12 months after end of treatment

Secondary Outcomes

duration of response

Time frame: 12 months after end of treatment

Progression free survival

Time frame: 12 months after end of treatment

adverse events

Time frame: 12 months after end of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.